K Ouriel - The lancet, 2001 - Elsevier Lower extremity peripheral arterial disease(PAD) most frequently presents with
pain during ambulation, which is known as “intermittent claudication”. Some
relief of symptoms is possible with exercise, pharmacotherapy, and ... Cited by 264 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] SB Freedman, JM Isner - Annals of internal medicine, 2002 - Am Coll Physicians A large body of evidence in animal models of ischemia shows that administration
of angiogenic growth factors, either as recombinant protein or by gene transfer,
can augment nutrient perfusion through neovascularization. Many cytokines ... Cited by 216 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org SE Epstein, R Kornowski, S Fuchs, HF Dvorak - Circulation, 2001 - Am Heart Assoc Although essentially unknown as a therapeutic concept as recently as a decade
ago, it is difficult now to open a cardiology journal, attend a cardiology
meeting, or scan a newspaper without being caught up in the excitement ... Cited by 143 - Related articles - BL Direct - All 5 versions
M Autiero, A Luttun, M Tjwa, P Carmeliet - Journal of Thrombosis and Haemostasis, 2003 - interscience.wiley.com Summary. In contrast to VEGF and its receptor VEGFR-2, PlGF and its receptor
VEGFR-1 have been largely neglected and therefore their potential for therapy
has not been previously explored. In this review, we describe the molecular ... Cited by 138 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org JM Isner, PR Vale, JF Symes, DW Losordo - Circulation research, 2001 - Am Heart Assoc Clinical trials of cardiovascular gene therapy, whether using viral (53%) or
nonviral (47%) vectors, have thus far disclosed no evidence indicative of
inflammatory or other complications, including death, directly attributable ... Cited by 124 - Related articles - BL Direct - All 5 versions
SB Freedman, JM Isner - Journal of Molecular and Cellular Cardiology, 2001 - Elsevier In animal models of ischemia, a large body of evidence indicates that
administration of angiogenic growth factors, either as recombinant protein or by
gene transfer, can augment nutrient perfusion through neovascularization. ... Cited by 117 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org R Morishita, M Aoki, N Hashiya, H Makino, K … - Hypertension, 2004 - Am Heart Assoc Therapeutic angiogenesis using angiogenic growth factors is expected to be a new
treatment for patients with critical limb ischemia (CLI). Because hepatocyte
growth factor (HGF) has potent angiogenic activity, we investigated the ... Cited by 105 - Related articles - BL Direct - All 13 versions
TA Khan, FW Sellke, RJ Laham… - Gene Therapy, 2003 - angiogenesis-center.org After extensive investigation in preclinical studies and recent clinical trials,
gene therapy has been established as a potential method to induce therapeutic
angiogenesis in ischemic myocardial and limb disease. Advancements in viral ... Cited by 102 - Related articles - View as HTML - BL Direct - All 7 versions
A Saaristo, T Veikkola, T Tammela, B Enholm, … - Journal of Experimental Medicine, 2002 - jem.rupress.org Recent work from many laboratories has demonstrated that the vascular
endothelial growth factor-C/VEGF-D/VEGFR-3 signaling pathway is crucial for
lymphangiogenesis, and that mutations of the Vegfr3 gene are associated ... Cited by 97 - Related articles - BL Direct - All 9 versions
S Mudaliar, MD, FACE, AR Chang, MD, RR … - Endocrine Practice, 2003 - AACE The thiazolidinediones are peroxisome proliferator- activated receptor-γ
agonists that constitute a new class of orally administered antidiabetic
compounds that decrease insulin resistance in patients with type 2 diabetes ... Cited by 100 - Related articles - BL Direct - All 2 versions
